TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: A post hoc analysis from a prospective cohort [0.03%]
TP53缺失作为儿童B细胞急性淋巴细胞白血病MRD依赖性风险因素的预后标志的探索性分析：前瞻性队列的事后分析
Yangyang Gao,Jun Li,Ning Wang et al.
Yangyang Gao et al.
The effect of TP53 alterations on childhood B-cell acute lymphoblastic leukemia (B-ALL) remains unclear. To investigate the prognostic value of TP53 deletion (TP53 del ) and TP53 mutation (TP53 mut ), this post hoc study used fluorescence i...
Two distinct fetal-type signatures characterize juvenile myelomonocytic leukemia [0.03%]
两种不同的胎儿型特征可描述幼年型粒单核细胞白血病
Marion Strullu,Chloé Arfeuille,Aurélie Caye-Eude et al.
Marion Strullu et al.
Juvenile myelomonocytic leukemia (JMML) is an aggressive clonal myeloproliferative neoplasm that affects infants and young children. The narrow window of onset suggests that age-related factors are involved in leukemogenesis. To investigate...
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype [0.03%]
轻度或中度血友病不总是轻度或中度出血性疾病：回到临床表现表型的话题上
Francesco Rodeghiero,Lisanna Ghiotto,Luca Pontalto et al.
Francesco Rodeghiero et al.
In a previous paper, a comprehensive clinicopathologic approach to mild and moderate bleeding disorders (MBD) was proposed by an international working group (IWG) as a part of a project promoted by the European Hematology Association (EHA) ...
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study [0.03%]
达特珠单抗方案与CyBorD方案在新诊断的IIIb期心脏阶段AL淀粉样变性患者中的比较：一项配对病例对照研究
Claudia Bellofiore,Marco Basset,Giuseppe Damiano Sanna et al.
Claudia Bellofiore et al.
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey [0.03%]
真性红细胞增多症患者和医师对治疗期望及症状学的看法：来自全球健康调查Landmark 2.0的见解
Claire N Harrison,David M Ross,Laura Maria Fogliatto et al.
Claire N Harrison et al.
Polycythemia vera (PV) is a myeloproliferative neoplasm associated with a high symptom and psychological burden, resulting in decreased quality of life (QoL). Patients with PV have an increased risk of cardiovascular (CV) complications, mak...
Chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Evaluating axicabtagene ciloleucel in the ZUMA-7 trial [0.03%]
弥漫性大B细胞淋巴瘤的嵌合抗原受体T细胞治疗：在ZUMA-7试验中评估axicabtagene ciloleucel的疗效
Vadim Lesan,Cristian Munteanu
Vadim Lesan
Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: A mixed-methods, prospective cohort study [0.03%]
异基因干细胞移植后镰状细胞疾病成人生活质量的变化：混合方法、前瞻性队列研究
Elisabeth Dovern,Sterre J A M Nijland,Annemarie M J Braamse et al.
Elisabeth Dovern et al.
Advances in conditioning regimens have made non-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) a viable curative option for adults with sickle cell disease (SCD). However, prospective studies comparing pre- and post...
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients [0.03%]
FIL MCL0208试验的长期结果：MCL患者自体干细胞移植后雷那度胺维持治疗与观察的比较
Rita Tavarozzi,Simone Ferrero,Andrea Evangelista et al.
Rita Tavarozzi et al.
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial [0.03%]
对于不能使用治愈性化疗的年长经典霍奇金淋巴瘤患者来说， Brentuximab单药治疗是一种切实可行且有效的治疗方法：来自前瞻性GHSG-NLG二期BVB试验的结果
Alexander Fosså,Daniel Molin,Paul J Bröckelmann et al.
Alexander Fosså et al.
Low-risk MDS-A spotlight on precision medicine for SF3B1- mutated patients [0.03%]
低危骨髓增生异常综合征——SF3B1突变患者精准医疗的聚焦点
Shoshana Burke,Onima Chowdhury,Kevin Rouault-Pierre
Shoshana Burke
A deep understanding of the biological mechanisms driving the pathogenesis of myelodysplastic neoplasms (MDS) is essential to develop comprehensive therapeutic approaches that will benefit patient's disease management and quality of life. I...